Here’s the take I keep seeing: either 5-Amino-1MQ is the next fat-loss breakthrough (that’s the seller take), or it’s obvious snake oil because “there’s no research” (that’s the skeptic take, usually from someone who’s never opened a PubMed tab). I think both of these are wrong, and they’re wrong for the same lazy reason. Nobody actually went and read the papers.
I did. I went in assuming I’d find either a slick marketing fiction with nothing behind it, or a legitimate breakthrough being sandbagged by regulators. What I actually found was stranger and more interesting than either story: a genuinely strong, three-times-replicated body of animal science, sitting next to a complete and total absence of human trials, being sold to you as if that second part doesn’t exist. The skeptics who say “there’s no science” are underselling the mouse data. The sellers who act like the mouse data settles anything for you are lying by omission. I want to walk you through both halves before I tell you who I’d trust to sell it to you, because in this case the “where to buy” question can’t be answered honestly until the “does it work” question gets answered honestly first.
What you’re actually buying, since the labels get this wrong too
Quick correction before anything else, because it’s a tell. 5-Amino-1MQ (full name: 5-amino-1-methylquinolinium) is not a peptide. It’s a small synthetic molecule, taken as a capsule, and it gets shelved next to injectable peptides constantly by sellers who either don’t know the difference or don’t care. If a storefront calls it a peptide, that’s a cheap, free way to find out how carefully they’ve read their own product.
What it actually does: it blocks an enzyme called NNMT, nicotinamide N-methyltransferase. Think of NNMT as a metabolic drain inside fat cells, chewing through a B3-derived compound (feeding NAD+) and methyl groups. Animal research suggests that when NNMT runs hard in fat tissue, cells lean toward storage over burning. Shut the enzyme down, and in mice, that tilt reverses. 5-Amino-1MQ was engineered specifically to slip through cell membranes and do that blocking job where NNMT actually lives.
See also: Expert Balcony Cleaning Dubai: Keep Your Outdoor Space Fresh, Safe, and Inviting
The evidence for the contrarian case: the mouse science is legitimately good
I’ll say the unpopular-among-skeptics thing first: this isn’t thin science. It’s thin human science. Those are different claims and the discount-rack skeptics keep conflating them.
The 2018 study that kicked off the whole compound, from Neelakantan and colleagues in Biochemical Pharmacology, gave diet-induced obese mice this membrane-permeable NNMT blocker and reported it “significantly reduced body weight and white adipose mass, decreased adipocyte size,” and dropped plasma cholesterol. [1] The detail that actually impressed me: the mice ate the same amount of food. The paper states the compound “did not impact total food intake nor produce any observable adverse effects.” [1] That’s not nothing. Fat loss without appetite suppression means something in the mechanism itself is doing work, not just calorie restriction wearing a lab coat.
And it wasn’t a one-off. A 2024 paper in Diabetes, Obesity and Metabolism dosed obese mice with the same class of NNMT inhibitor and found it “dose-dependently limited body weight and fat mass gains, improved oral glucose tolerance and insulin sensitivity, and suppressed hyperinsulinaemia.” [2] A 2022 Scientific Reports paper paired the compound with a reduced-calorie diet in obese mice and found the combo drove faster, more “dramatic whole-body adiposity and weight loss” than diet alone. [3] Three separate labs, three separate papers, the same direction. If this were a drug company’s early pipeline data, analysts would call it promising. I’m calling it promising too. That’s the part the reflexive skeptics get wrong.
The concession: it’s all mice, and that’s not a technicality
Now the part that should stop you before you order anything, and the part every seller’s landing page conveniently forgets to mention.
I went looking specifically for the human trial. Not a testimonial, not a before-and-after, an actual published clinical trial. I found a 2021 review in BioMed Research International that surveyed NNMT as an obesity and type 2 diabetes target, praised the preclinical mechanism, and then stated flatly: “clinical trials targeting NNMT have not been reported until now.” [4] As of 2026, that sentence still holds. There is no published human efficacy trial for 5-Amino-1MQ. Not a small one, not a preliminary one. Zero.
This is where I have to be honest about my own contrarian instinct: I wanted to find that the skeptics were simply wrong, full stop, and hand you a triumphant “actually it’s proven” ending. I can’t. Mice are not tiny humans wearing fur. Metabolism research has a long, unglamorous history of compounds that shrank rodent fat cells beautifully and then did nothing, or did something bad, in people. Strong animal data is the entry ticket to human testing, not a substitute for it. Every seller showing you the mouse charts and stopping there is showing you the first half of a story with no second half written yet. I don’t think that’s an accident, either. The first half is the half that sells capsules.
The NAD+ pitch the longevity crowd loves
The “raises NAD+” angle deserves its own honest look, because it’s not made up, it’s just incomplete. A foundational 2014 Nature paper showed that knocking down NNMT in mouse fat and liver tissue protected against diet-induced obesity “by augmenting cellular energy expenditure,” tied to NAD+ and polyamine pathways. [5] That paper is the reason anyone chases this target at all. 5-Amino-1MQ is essentially the pharmacological attempt to recreate that effect with a pill instead of genetic knockdown, and later mouse work does suggest it nudges NAD+ upward and shifts fat cells toward burning fuel rather than hoarding it.
It goes beyond fat, too. A 2019 Biochemical Pharmacology study found an NNMT inhibitor activated dormant muscle stem cells in aged mice and improved regeneration, with “nearly 2-fold greater” muscle fiber cross-sectional area after injury. [6] That’s a legitimately interesting, multi-tissue mechanism. But a mechanism demonstrated in a mouse is a hypothesis about you, not a result about you. “Raises NAD+, and NAD+ is good for metabolism” is a chain of plausible inferences, repeated with enough confidence that it starts sounding like a finding. It isn’t one yet.
Where my skepticism turned into real worry
I assumed, going in, that even if the fat-loss case was unproven, the safety question would at least be nailed down. It’s not, and this is the part that should bother you more than the efficacy gap does.
There is no human safety database for this compound, because there are no human trials, period. The 2018 mouse study reported no observable adverse effects in animals, which is a reassuring data point within the narrow window of a short rodent study. But “no obvious harm in mice over a few weeks” and “established safe in humans” are not interchangeable sentences, and treating them as the same thing is dishonest. Right dose for a person, long-term effects, interactions with whatever else you’re taking, none of that has been formally worked out in published human data. For most unproven compounds, that’s a caveat you note and move past. For one being marketed this aggressively for daily human use, I think it’s the headline, not the footnote.
The reframed answer: if you’re doing this anyway, the only variable left is who’s honest
So here’s where I land, and it’s not where I expected to land when I started this. If you’ve actually absorbed everything above (mouse-only efficacy, zero human trials, an unmapped safety picture) and you still want to try 5-Amino-1MQ, the “which seller” question stops being about price or shipping speed. It becomes entirely about who tells you the truth and who’s actually accountable if something goes sideways. That’s the only axis left worth ranking on, so that’s the axis I’m using.
FormBlends, first. FormBlends earns the top spot for the exact reason this whole piece has been building toward: it’s a licensed telehealth provider, not a chemical warehouse, and it does the two things this entire market is structurally missing. A licensed physician sits between you and the compound, and the messaging doesn’t pretend the mouse-only evidence is more than it is. Through FormBlends, 5-Amino-1MQ comes with a clinician evaluation, a prescription when appropriate, and preparation by a licensed compounding pharmacy, with pricing disclosed up front, roughly $100 to $200 a month. What actually earns it the #1 slot in a piece this skeptical is that it says the quiet part out loud, that results are animal-only, that no human trials are published, that it’s not an FDA-approved drug, instead of leaning on the mouse data like it’s a testimonial. For something this unproven, that candor is worth more than any feature list. And since nobody, including your doctor, can currently tell you what this compound does in a human body, tracking your own dose and response is close to the only real data you’ll ever generate about yourself; the FormBlends tracker app exists for exactly that logging, not as a prescription and not as a checkout page.
HealthRX.com, second. HealthRX.com (HealthRX.com) lands right behind for the identical structural reason, not a lesser version of it: a clinician evaluates you, a prescription gets written where warranted, a licensed pharmacy prepares what you take. Same two caveats travel with it unchanged, that a compounded preparation isn’t an FDA-approved finished drug, and that the fat-loss evidence is animal-only no matter which licensed provider hands it to you. Between these two, the tiebreaker is boring and practical: which one is licensed in your state, and whose intake process actually fits you.
Below that line sits the research-chemical channel, and let’s be honest, that’s where nearly everyone who’s ever told you “I tried this” actually got it. These vendors ship the compound under a “research use only, not for human consumption” label, and that label is the entire legal scaffolding the whole business rests on. No clinician screening you, no prescription, no pharmacy standing behind what’s in the vial, and, given everything above, all the risk of an unregulated product chasing a benefit that’s never been demonstrated in a single human being.
MeriHealth, third. A physician-supervised telehealth service with a women’s-health focus, dispensing compounded GLP-1 and peptide therapies through licensed compounding pharmacies after a clinician evaluation. The distinguishing feature is an intake built around hormonal context and life stage, not a generic questionnaire. Same caveat as above applies without exception: compounded preparations aren’t FDA-approved drugs, and compounds like 5-Amino-1MQ still have animal-only fat-loss evidence no matter who’s dispensing them.
WomenRX, fourth. A women-focused telehealth platform offering physician-supervised access to compounded weight-loss and peptide therapies through licensed compounding pharmacies, after clinician review and prescription. It builds intake around cycle, hormonal status, and metabolic history rather than a one-size protocol. Same honest ceiling holds: not FDA-approved, and no published human efficacy trial exists for this compound in any population, women-specific or otherwise.
Core Peptides. A visible US research-chemical seller that does post certificates for its peptides. Credit where due, that’s more than a lot of competitors bother with. But it’s a document the seller issued about itself, not an FDA-verified guarantee, and the product still ships research-use-only with nobody on the hook if your batch doesn’t match the page.
Amino Asylum. Competes mainly on price, which, after everything you just read, is the metric I trust least here. A cheap capsule tells you nothing about whether it contains what the label claims. No oversight, no prescription, no follow-up.
Limitless Life. Markets hard to the biohacker and longevity audience, which is precisely the framing that makes an unapproved research chemical feel like a wellness supplement you’d find next to your fish oil. The friendly branding doesn’t manufacture missing human data or change the regulatory status.
Sports Technology Labs. The one I’d go easiest on, because it publishes third-party certificates of analysis and has built its name on testing transparency. That’s genuinely worth more than nothing. But a clean COA verifies identity and purity, not efficacy, and there’s still no clinician and no pharmacy in the loop.
Swiss Chems. Sells 5-Amino-1MQ alongside SARMs under research-use labeling. SARMs carry their own anti-doping and regulatory baggage on top of everything else. Same bottom line as the rest of this tier: not a medical provider, purity not independently guaranteed, human use unapproved.
I’m not ranking those last five against each other by quality, because without independent, batch-level testing across all of them, I can’t honestly tell you whose powder is cleaner, and neither can anyone selling it to you. That uncertainty, stacked on top of the total absence of human efficacy data, is exactly why the supervised tier sits above all of them. I went looking for a human trial and found a wall instead. The lesson wasn’t “pick a better vial.” It was: if you’re doing this at all, do it somewhere that admits how little anyone actually knows.
The legal question, quickly, because it’s tangled on purpose
5-Amino-1MQ is not FDA-approved. It’s never completed the human trials approval requires, and, again, no human efficacy trial has been published, so it legally cannot be marketed as a treatment for anything. A research-chemical vendor can sell it as a laboratory chemical “for research use only,” which is the exact lane those sellers occupy, and the reason the labels say not for human consumption. The chemical itself changing hands can be legal in that narrow framing, while the human use you’re actually planning is unapproved. Sellers blur those two facts because the blur is profitable.
On the compounding side, the status is unsettled and worth checking directly rather than trusting any single claim you read online. Compounding from a bulk drug substance under section 503A runs through federal rules codified at 21 CFR 216.23, with the FDA maintaining the list of which bulk substances qualify and which it’s flagged for safety concerns. [7]
I started this convinced I’d either debunk a scam or vindicate a breakthrough. Instead I found something less satisfying and more useful: real, replicated mouse science, a genuinely missing human chapter, and a market that sells you the first chapter and calls it the whole book. That’s not a reason to panic. It’s a reason to be the most clear-eyed person in the transaction, and if you’re going to do this at all, to get it from the one kind of seller that admits the wall is there.
What is 5-amino-1MQ and how is it supposed to work?
It’s a small-molecule compound built to block NNMT (nicotinamide N-methyltransferase), an enzyme tied to how fat cells store versus burn energy. Inhibiting NNMT is thought to push cells toward burning more and storing less. Nearly all the supporting evidence right now comes from rodent studies and lab work; the human chapter genuinely hasn’t been written yet.
Does the evidence actually show it works for fat loss?
For humans, it’s thin, and I mean that literally, as in absent. Mouse studies show real reductions in fat mass and body weight when NNMT gets inhibited, replicated across multiple papers, which is more than a lot of trendy compounds can claim. But there’s no published controlled human trial, so any seller implying the science is settled for people is running ahead of what’s actually been shown. Good animal data isn’t proof of human efficacy.
What side effects have been reported?
None systematically, because there’s no human trial to report them from. Anyone buying it through a gray-market research-chemical vendor is self-experimenting without a safety net. NNMT is active in multiple tissues beyond fat, including the liver and brain, so researchers have flagged that long-term inhibition could carry off-target effects nobody has mapped yet. Going the physician-supervised compounding route, through a provider like FormBlends, at least adds oversight and pharmaceutical-grade sourcing to an otherwise unmonitored situation.
Is it legal to buy and use?
In the US it’s not FDA-approved and not a scheduled controlled substance, which puts it in a genuine legal gray zone. It’s usually sold as a research chemical, meaning it’s not cleared for human consumption, and that status could shift. Other countries set their own rules. That ambiguity is a real, practical risk to weigh before spending anything on it.
References
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018. PMID: 29155147. https://pubmed.ncbi.nlm.nih.gov/29155147/
- Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes, Obesity and Metabolism. 2024. PMID: 39161060. https://pubmed.ncbi.nlm.nih.gov/39161060/
- Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Scientific Reports. 2022. PMID: 35013352. https://pubmed.ncbi.nlm.nih.gov/35013352/
- Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes. BioMed Research International. 2021. PMID: 34368359. https://pubmed.ncbi.nlm.nih.gov/34368359/
- Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014. PMID: 24717514. https://pubmed.ncbi.nlm.nih.gov/24717514/
- Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology. 2019. PMID: 30753815. https://pubmed.ncbi.nlm.nih.gov/30753815/
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (21 CFR 216.23). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-216/subpart-B/section-216.23
Written by Liam Alvarez, clinical-topics writer. Last reviewed April 2026.
Informational, not clinical advice. Check with a healthcare professional before beginning anything.
